Carnegie Strategifond D vs UBS Lux Equity Fund Biotech USD

Carnegie Strategifond D vs UBS Lux Equity Fund Biotech USD

1. Carnegie Strategifond D

  • Security

    Carnegie Strategifond D

  • Fee

    1.50%

  • ISIN

    SE0013525276

  • Holdings

    24

2. UBS Lux Equity Fund Biotech USD

  • Security

    UBS Lux Equity Fund Biotech USD P-acc

  • Fee

    2.25%

  • ISIN

    LU0069152568

  • Holdings

    9

Fund Holdings

We have information about 34 holdings in Carnegie Strategifond D, where the largest holding is Investor (6.12), followed by Essity (4.67) and Volvo (4.4). In comparison with UBS Lux Equity Fund Biotech USD, we have 11 holdings where Regeneron Pharmaceuticals is the largest holding (10.04), followed by Moderna (9.21) and Vertex (8.44).

All Holdings

Here we compare the holdings in Carnegie Strategifond D and UBS Lux Equity Fund Biotech USD.

Carnegie Strategifond D UBS Lux Equity Fund Biotech USD
1. Investor B
Sweden
6.12 %
1. Regeneron Pharmaceuticals Inc
10.04 %
2. Essity B
Sweden
4.67 %
2. Moderna Inc
9.21 %
3. Volvo B
Sweden
4.4 %
3. Vertex Pharmaceuticals Inc
8.44 %
4. Skanska B
Sweden
3.32 %
4. Alnylam Pharmaceuticals Inc
8.08 %
5. Assa Abloy B
Sweden
2.83 %
5. AbbVie Inc
USA
4.91 %
6. Epiroc B
Sweden
2.73 %
6. Gilead Sciences Inc
USA
4.66 %
7. SCA B
Sweden
2.7 %
7. Amgen Inc
USA
4.43 %
8. Atlas Copco B
Sweden
2.54 %
8. BioNTech SE
4.13 %
9. Alfa Laval
Sweden
2.53 %
9. Karuna Therapeutics Inc
3.75 %
10. Holmen B
Sweden
2.46 %
-
11. Lifco B
Sweden
2.4 %
-
12. Sampo Oyj A
Finland
2.12 %
-
13. Pandox B
Sweden
1.81 %
-
14. John Mattson Fastighetsföretagen
Sweden
1.8 %
-
15. Nordea Bank Abp
Finland
1.73 %
-
16. Synsam Group Sweden AB
Sweden
1.73 %
-
17. Handelsbanken A
Sweden
1.72 %
-
18. Hennes & Mauritz B
Sweden
1.71 %
-
19. Atrium Ljungberg B
Sweden
1.53 %
-
20. Karnov Group Sweden AB
Sweden
1.26 %
-
21. Axfood AB
Sweden
1.16 %
-
22. Getinge B
Sweden
1.15 %
-
23. Orkla Foods AS
Norway
1.02 %
-
24. Autoliv SDB
Sweden
1.02 %
-

The list of fund holdings was last updated on July 27, 2025.